News
VTVT
30.14
-2.32%
-0.72
Weekly Report: what happened at VTVT last week (0803-0807)?
Weekly Report · 4d ago
Analysts Conflicted on These NA Names: LATAM Airlines Group SA Sponsored ADR (LTM), vTv Therapeutics (VTVT) and Once Upon a Farm, PBC (OFRM)
TipRanks · 4d ago
vTv Therapeutics (VTVT) Gets a Buy from Roth MKM
TipRanks · 08/07 12:37
vTv Therapeutics Price Target Cut to $42.00/Share From $45.00 by HC Wainwright & Co.
Dow Jones · 08/06 18:53
vTv Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/06 18:53
HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42
Benzinga · 08/06 18:43
vTv Therapeutics price target lowered to $42 from $45 at H.C. Wainwright
TipRanks · 08/06 16:15
*VTv Therapeutics 2Q Rev $0.00 >VTVT
Dow Jones · 08/06 12:00
VTv Therapeutics: Q2 Earnings Snapshot
Barchart · 08/06 07:22
Weekly Report: what happened at VTVT last week (0727-0731)?
Weekly Report · 08/03 09:01
Weekly Report: what happened at VTVT last week (0720-0724)?
Weekly Report · 07/27 09:01
Weekly Report: what happened at VTVT last week (0713-0717)?
Weekly Report · 07/20 09:01
Abbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 07/17 12:00
BlackRock To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 07/16 11:57
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)
TipRanks · 07/16 10:50
vTv Therapeutics Is Maintained at Buy by BTIG
Dow Jones · 07/16 09:56
vTv Therapeutics Price Target Raised to $57.00/Share From $49.00 by BTIG
Dow Jones · 07/16 09:56
BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57
Benzinga · 07/16 09:46
Weekly Report: what happened at VTVT last week (0706-0710)?
Weekly Report · 07/13 09:01
Weekly Report: what happened at VTVT last week (0629-0703)?
Weekly Report · 07/06 09:01
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.